BCL2 and myelodysplastic syndrome: We therefore concluded that the known sensitivity of high-risk MDS samples to ABT-199 [7] might not be determined by BCL-2 mRNA expression alone, but might be caused by BCL-2 protein levels or, alternatively, by expression of BCL-2 family members other than BCL-2 itself.